Comparative Treatment Outcomes for Idiopathic Subglottic Stenosis: 5-Year Update.
Comparative Treatment Outcomes for Idiopathic Subglottic Stenosis: 5-Year Update.
复制标题
特发性声门下狭窄的比较治疗结果：5 年更新。
DOI：
10.1002/ohn.190
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
A. Gelbard
中科院分区：
文献类型：
--
作者：
W. Tierney;Li;Sheau;Lynne D Berry;Catherine Anderson;Milan R Amin;M. Benninger;J. Blumin;J. Bock;Paul C Bryson;Paul F Castellanos;Matthew S Clary;Seth M. Cohen;Brianna K. Crawley;S. Dailey;James J. Daniero;A. de Alarcón;Donald T. Donovan;E. Edell;D. Ekbom;Daniel S. Fink;Ramon A Franco;C. Gaelyn Garrett;Elizabeth A. Guardiani;A. Hillel;H. Hoffman;N. Hogikyan;R. Howell;Michael M Johns;J. Kasperbauer;S. Khosla;C. Kinnard;Robbi A Kupfer;Alexander J. Langerman;R. Lentz;Robert R Lorenz;D. Lott;Samir S Makani;Fabien Maldonado;L. Matrka;Andrew J. McWhorter;A. Merati;M. Mori;J. Netterville;K. O'Dell;J. Ongkasuwan;G. Postma;Lindsay S Reder;S. Rohde;Brent E. Richardson;O. Rickman;Clark A. Rosen;Matthew L. Rohlfing;Michael J Rutter;Guri S Sandhu;J. Schindler;G. Schneider;R. Shah;Andrew G Sikora;R. Sinard;Marshall E Smith;Libby J. Smith;A. Soliman;Sigríður Sveinsdóttir;D. Veivers;S. Verma;Paul M. Weinberger;P. Weissbrod;C. Wootten;Y. Shyr;David O Francis;A. Gelbard
北美气道协作组织（NoAAC）之前发表了一项为期3年的多机构前瞻性队列研究，显示了3种原发性声门下狭窄（iSGS）主要手术技术之间的治疗有效性差异。在本报告中，我们更新了这些发现，包括5年的治疗有效性评估数据。NoAAC队列中的患者再入组2年，并使用预先指定的已发表方案进行随访。与既往数据一致，对487例iSGS患者进行了5年的前瞻性观察，结果显示治疗有效性因治疗方式而异。环状气管切除术的复发率最低（5%），其次是内镜下切除加辅助药物治疗（30%）和内镜下扩张（50%）。这些数据支持最初的观察结果，并继续为医疗服务提供者和患者提供纵向决策的价值。证据等级：2-前瞻性队列研究。
The North American Airway Collaborative (NoAAC) previously published a 3-year multi-institutional prospective cohort study showing variation in treatment effectiveness between 3 primary surgical techniques for idiopathic subglottic stenosis (iSGS). In this report, we update these findings to include 5 years of data evaluating treatment effectiveness. Patients in the NoAAC cohort were re-enrolled for 2 additional years and followed using the prespecified published protocol. Consistent with prior data, prospective observation of 487 iSGS patients for 5 years showed treatment effectiveness differed by modality. Cricotracheal resection maintained the lowest rate of recurrent operation (5%), followed by endoscopic resection with adjuvant medical therapy (30%) and endoscopic dilation (50%). These data support the initial observations and continue to provide value to providers and patients navigating longitudinal decision-making. Level of evidence: 2-prospective cohort study.